BTI
VRTX icon

Blue Trust Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Blue Trust Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Buy
1,677
+1,252
+295% +$555K 0.01% 339
2026
Q1 		$190K Sell
425
-912
-68% -$425K ﹤0.01% 790
2025
Q4 		$606K Buy
1,337
+769
+135% +$331K 0.01% 421
2025
Q3 		$222K Sell
568
-24
-4% -$10K ﹤0.01% 758
2025
Q2 		$264K Buy
592
+19
+3% +$8.76K ﹤0.01% 669
2025
Q1 		$278K Sell
573
-61
-10% -$28.4K ﹤0.01% 590
2024
Q4 		$255K Sell
634
-2,077
-77% -$963K ﹤0.01% 567
2024
Q3 		$1.27M Buy
2,711
+1,268
+88% +$609K 0.02% 220
2024
Q2 		$603K Buy
1,443
+1,248
+640% +$542K 0.01% 323
2024
Q1 		$81.5K Sell
195
-303
-61% -$128K ﹤0.01% 768
2023
Q4 		$173K Sell
498
-628
-56% -$232K ﹤0.01% 493
2023
Q3 		$397K Buy
1,126
+108
+11% +$37.8K 0.01% 291
2023
Q2 		$321K Sell
1,018
-189
-16% -$63.7K 0.01% 296
2023
Q1 		$349K Sell
1,207
-42
-3% -$12.6K 0.01% 369
2022
Q4 		$361K Buy
1,249
+1,006
+414% +$307K 0.01% 317
2022
Q3 		$68K Buy
243
+113
+87% +$32.5K ﹤0.01% 652
2022
Q2 		$34K Buy
+130
New +$34.8K ﹤0.01% 806

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Blue Trust Inc's VRTX Position: Q2 2026 in Review

Blue Trust Inc increased its Vertex Pharmaceuticals (VRTX) stake by 295% in Q2 2026, buying an estimated $555K and bringing the position to 1,677 shares worth $833K. The position accounts for 0.01% of the portfolio, ranked #339.

Blue Trust Inc first reported a position in VRTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.27M in Q3 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Blue Trust Inc held 1,677 shares of Vertex Pharmaceuticals worth $833K as of Q2 2026.
  • Blue Trust Inc bought 1,252 Vertex Pharmaceuticals shares in Q2 2026, an estimated $555K.
  • Vertex Pharmaceuticals made up 0.01% of Blue Trust Inc's portfolio in Q2 2026, its #339 holding.
  • Blue Trust Inc first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust Inc's Vertex Pharmaceuticals position peaked at $1.27M in Q3 2024.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.